Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Chad E. Mire, Robert W. Cross, Joan B. Geisbert, Viktoriya Borisevich, Krystle N. Agans, Daniel J. Deer, Megan L. Heinrich, Megan M. Rowland, Augustine Goba, Mambu Momoh, Mathew L. Boisen, Donald S. Grant, Mohamed Fullah, Sheik Humarr Khan, Karla A. Fenton, James E. Robinson, Luis M. Branco, Robert F. Garry, Thomas W. Geisbert

Research output: Contribution to journalArticlepeer-review

98 Scopus citations

Abstract

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.

Original languageEnglish (US)
Pages (from-to)1146-1149
Number of pages4
JournalNature Medicine
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2017

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever'. Together they form a unique fingerprint.

Cite this